COMMUNIQUÉS West-GlobeNewswire

Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
03/06/2025
Dr. James Galvin of the University of Miami to Serve as Lead Investigator First Site Initiated: Banner Sun Health Research Institute PURCHASE, N.Y., June 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “ [...]
Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations
03/06/2025
Libby brings strong team building, growth, and sales operations and systems skills to Sanuwave after a career of growing startups into mid- and large-sized companies. EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE [...]
XPOLAR X Series: The Innovative Device Redefining Sports Recovery
03/06/2025
SHENZHEN, China, June 03, 2025 (GLOBE NEWSWIRE) -- XPOLAR, an innovator in sports recovery and wellness technology, officially debuted its X2 Recovery Device at CES 2025. Designed to meet the demand for smarter, more [...]
Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
03/06/2025
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today the early tender results in connection with its previously announced tender offers [...]
Cartesian Therapeutics Announces New Employment Inducement Grants
03/06/2025
FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the [...]
Kraig Biocraft Laboratories Issues a Letter to Shareholders on Recent Advancements and Potential Recombinant Spider Silk Deliveries in 2025
03/06/2025
ANN ARBOR, Mich., June 03, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, issues a letter to shareholders. Dear [...]
Vanqua Bio to Present at Upcoming Scientific Conferences
03/06/2025
CHICAGO, June 03, 2025 (GLOBE NEWSWIRE) -- Vanqua Bio , a clinical-stage biopharmaceutical company, announced that the company will present interim Phase 1 data for its lead clinical program, VQ-101, at two upcoming [...]
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/06/2025
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired [...]
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
03/06/2025
PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of [...]
Conavi Medical Announces New Grant of Stock Options
03/06/2025
TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“ Conavi Medical ” or the “ Company ”), announced that its board of directors (the “Board”) has approved grants of stock [...]
Priothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen
03/06/2025
Highly experienced clinical development executive joins Priothera Board as mocravimod progresses through global Phase 3 trial as adjunctive and maintenance treatment in AML patients undergoing allo-HCT Saint-Louis, [...]
Oculis to Participate in Upcoming June Investor Conferences
03/06/2025
ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases [...]
Oculis to Participate in Upcoming June Investor Conferences
03/06/2025
ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases [...]
Kamari Pharma Announces Closing of $23 Million Financing to Advance its First-In-Class Oral TRPV3 Inhibitor for Rare Genetic Skin Diseases
03/06/2025
Financing co-led by new investor BRM Group and existing investor Pontifax Lead program KM023 is a first-in-class oral TRPV3 inhibitor entering clinical development for the treatment of three rare genetic skin diseases; [...]
CancerVax Scientists Featured on Cytiva’s “Discovery Matters” Podcast Discussing Universal Cancer Vaccine Platform
03/06/2025
Dr. George Katibah and Dr. Adam Grant describe the features and progress of the Company’s revolutionary technology Lehi, June 03, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah – June 3rd, 2025 – CancerVax, Inc., the developer of [...]
Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00
03/06/2025
Press release Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00 Dijon, France 03 June 2025 (07.30 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the [...]
Maxim Group initie la couverture de l'action CROSSJECT avec une note à l’achat et un prix cible de 4,00 €
03/06/2025
Communiqué de presse Maxim Group initie la couverture de l'action CROSSJECT avec une note à l’achat et un prix cible de 4,00 € Dijon, France le 3 juin 2025 (07h30 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), [...]
Addex Convenes Annual General Meeting 2025
03/06/2025
Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for [...]
Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
03/06/2025
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options 1 First Phase III study in ES-SCLC first- [...]

Pages